




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 9/00, 47/48	A1	(11) International Publication Number: WO 95/03783 (43) International Publication Date: 9 February 1995 (09.02.95)		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> (21) International Application Number: PCT/US93/07292 (22) International Filing Date: 2 August 1993 (02.08.93) (60) Parent Applications or Grants (63) Related by Continuation <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/490,066 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>6 March 1990 (06.03.90)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/795,752 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>21 November 1991 (21.11.91)</div> </div> (71) Applicant (for all designated States except US): HOUSTON BIOTECHNOLOGY INCORPORATED [US/US]; 3608 Research Forest Drive, The Woodlands, TX 77381 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KELLEHER, Peter, J. [US/US]; 6 North Waxberry Road, The Woodlands, TX 77381 (US). LAM, Dominic, M., K. [US/US]; 9 East Wedgewood Glen, The Woodlands, TX 77381 (US). TAR-SIO, Maureen, P. [US/US]; 4734 Sabre Lane, Manlius, NY 13104 (US). (74) Agent: RAE-VENTER, Barbara; Fish & Richardson, Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US). </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> </td> </tr> </table>			(21) International Application Number: PCT/US93/07292 (22) International Filing Date: 2 August 1993 (02.08.93) (60) Parent Applications or Grants (63) Related by Continuation <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/490,066 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>6 March 1990 (06.03.90)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/795,752 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>21 November 1991 (21.11.91)</div> </div> (71) Applicant (for all designated States except US): HOUSTON BIOTECHNOLOGY INCORPORATED [US/US]; 3608 Research Forest Drive, The Woodlands, TX 77381 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KELLEHER, Peter, J. [US/US]; 6 North Waxberry Road, The Woodlands, TX 77381 (US). LAM, Dominic, M., K. [US/US]; 9 East Wedgewood Glen, The Woodlands, TX 77381 (US). TAR-SIO, Maureen, P. [US/US]; 4734 Sabre Lane, Manlius, NY 13104 (US). (74) Agent: RAE-VENTER, Barbara; Fish & Richardson, Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US).	(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(21) International Application Number: PCT/US93/07292 (22) International Filing Date: 2 August 1993 (02.08.93) (60) Parent Applications or Grants (63) Related by Continuation <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/490,066 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>6 March 1990 (06.03.90)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>US</div> <div>07/795,752 (CIP)</div> </div> <div style="display: flex; justify-content: space-between;"> <div>Filed on</div> <div>21 November 1991 (21.11.91)</div> </div> (71) Applicant (for all designated States except US): HOUSTON BIOTECHNOLOGY INCORPORATED [US/US]; 3608 Research Forest Drive, The Woodlands, TX 77381 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KELLEHER, Peter, J. [US/US]; 6 North Waxberry Road, The Woodlands, TX 77381 (US). LAM, Dominic, M., K. [US/US]; 9 East Wedgewood Glen, The Woodlands, TX 77381 (US). TAR-SIO, Maureen, P. [US/US]; 4734 Sabre Lane, Manlius, NY 13104 (US). (74) Agent: RAE-VENTER, Barbara; Fish & Richardson, Suite 100, 2200 Sand Hill Road, Menlo Park, CA 94025 (US).	(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>			
(54) Title: POLYMERIC DEVICE FOR THE DELIVERY OF IMMUNOTOXINS FOR THE PREVENTION OF SECONDARY CATARACT				
(57) Abstract <p>Intraocular devices together with methods for their preparation and use are provided, which are capable of sustained release of an antiproliferative agent, particularly an immunotoxin comprising a cytotoxic moiety. The intraocular devices are implanted in the eye where the immunotoxin is released from the intraocular device. The device may be used to inhibit proliferation of remnant lens epithelial cells, particularly after extracapsular cataract extraction. The components of the device can be provided as kits, but preferably are provided in a form suitable for use with an IOL or coated directly onto the surface of an IOL.</p>				
<div style="display: flex; align-items: center; justify-content: center; gap: 20px;"> <div style="text-align: center;">  <p>Immunotoxin- polymer Solution</p> </div> <div style="font-size: 2em;">+</div> <div style="text-align: center;">  <p>IOL</p> </div> <div style="font-size: 2em;">=</div> <div style="text-align: center;">  <p>Immunotoxin- coated IOL</p> </div> </div>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

POLYMERIC DEVICE FOR THE DELIVERY OF IMMUNOTOXINS
FOR THE PREVENTION OF SECONDARY CATARACT

INTRODUCTION

Field of the Invention

This invention relates to an intraocular polymeric device and methods for its preparation and use, wherein the polymeric device comprises a polymer and at least one cytotoxic agent, particularly an immunotoxin for prevention and treatment of secondary cataracts.

Background

An intact posterior lens capsule is required for implantation of a wide variety of intraocular lenses. A surgical technique that preserves the posterior lens capsule, and which has found use in the treatment of cataracts, is generically termed extracapsular cataract extraction. The technique includes extracapsular cataract extraction, phacoemulsification, endocapsular extraction and intercapsular extraction. Newer methods of extracapsular cataract extraction under development, such as the Kelman phaco fly, would remove a cataract through a puncture of the lens capsule and refill the lens capsule bag with a flexible substance or an inflatable lens to restore vision and to preserve or restore natural accommodation.

Extracapsular cataract extraction is a desirable method for removing cataracts due to a lower incidence of post-operative complications such as cystoid macular edema and possible retinal detachment.

However, this surgical method is accompanied by a significant incidence of posterior lens capsule opacification, which may require additional surgical procedures such as posterior capsulotomy or repolishing of the posterior lens capsule to provide

2.

good vision. Virtually all pediatric patients and approximately 50% of adult patients undergoing extracapsular cataract extraction develop an opaque secondary cataract within 3 to 5 years.

5 The pathogenesis of posterior lens capsule opacification after extracapsular cataract extraction is reported to be due to proliferation of remnant lens epithelial cells on the posterior lens capsule to form abortive lens "fibers" and "bladder" cells
10 (i.e., Elschnig's pearls). Various cytotoxic agents are reported to inhibit this secondary cataract formation or posterior lens capsule opacification, including vincristine and vinblastine. Radiation has also been tried and was reported to be promising.
15 Methotrexate and retinoic acid have been reported for instillation in the anterior chamber of the eye to kill residual lens epithelial cells and thus prevent posterior lens capsule opacification. These methods are relatively non-specific and can damage and/or
20 kill other cells in addition to the lens epithelial cells.

 Techniques which are designed to more specifically kill lens epithelial cells have included introduction of immunotoxins capable of binding
25 specifically to residual lens epithelial cells on the lens capsule remnant at the time of cataract surgery. These immunotoxins have been shown to inhibit proliferation of lens epithelial cells in vitro. However, the immunotoxin activity is both dose and
30 time dependent and it is difficult to maintain the immunotoxin in the posterior chamber at a concentration and for a time sufficient to prevent proliferation of and/or to kill the residual lens epithelial cells. The immunotoxin passes through the
35 pupil into the anterior chamber where it is lost through normal aqueous outflow. It would therefore be of interest to develop methods and compositions

3.

for retarding loss of the immunotoxin from the posterior chamber for use in preventing secondary cataract formation or posterior lens capsule opacification. Such a device would have the advantage of providing a sufficient concentration of immunotoxin in the vicinity of the eye for a time sufficient to kill any lens epithelial cells remaining in the eye after extracapsular extraction.

10 Relevant Literature

Biodegradable microcapsules for use in the eye are disclosed in Wang (U.S. Patent 4,853,224). An eyeball medication dispensing tablet has been disclosed in U.S. Patent 3,416,530. U.S. Patent 4,526,938 discloses copolymers which can be used to provide for continuous release of polypeptides. See also Heyrman, et al., (1989) *J. Cataract Refract. Surg.*, 15:169-175.

Examples of polymeric delivery systems include Sherwood, et al. (1992) *Bio/Technology* 10:1446-1449; Hora, et al. (1990) *Bio/Technology* 8:755-757.

Immunotoxins and their use for treating secondary cataracts are described in U.S. Patents 4,871,350 and 4,432,751 and European Patent 0088606. U.S. Patent No. 4,432,751 also discloses use of a combination of monoclonal antibodies and complement for preventing secondary cataracts. Complement-fixing monoclonal antibodies which bind specifically with lens epithelial cells and have low or no cross-reactivity with other cells found in the anterior segment of the eye are disclosed in U.S. Patent 5,202,252. The use of sugars such as trehalose to prepare antibodies for storage is described in Rowser (U.S. Patent 4,891,319).

SUMMARY OF THE INVENTION

A novel intraocular device, together with methods of preparation and use, is provided for treatment and/or prevention of secondary cataracts.

5 The device comprises a biologically inert polymer and at least one cytotoxic agent, particularly an immunotoxin, capable of binding specifically to lens epithelial cells. The cytotoxic agent is associated reversibly with the polymer so as to provide for

10 sustained delivery of the cytotoxic agent following implantation of the device into the eye. The intraocular device is prepared in several ways including by immersing a polymer matrix in a solution of a cytotoxic agent whereby the cytotoxic agent is

15 pulled into the matrix by capillary action, by mixing the cytotoxic agent with the polymer prior to association with a support, such as an intraocular lens (IOL), or by coating a polymer matrix bound covalently or non-covalently to a support, such as an

20 IOL, with the cytotoxic agent. In use, the intraocular device is introduced into the anterior or posterior chamber of the eye during or following cataract surgery. The cytotoxic agent is

25 continuously released from the intraocular device in the vicinity of the posterior chamber at a concentration and for a time sufficient to kill any residual lens epithelial cells thus preventing the formation of secondary cataracts.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1 shows preparation of an immunotoxin coated IOL starting from a mixture of immunotoxin and polymer in solution.

35 Figure 2 shows preparation of an immunotoxin coated IOL using a two-step procedure: The polymer is first coated onto the IOL, which is then interacted with the immunotoxin solution. Upper view

5.

is IOL "edge" view; the intraocular device covers essentially the entire IOL surface. Lower view is IOL "face" view; the intraocular device essentially is a ring around the IOL.

5 Figure 3 shows the structure of a typical IgG antibody.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

10 The present invention relates to intraocular devices for preventing and/or treating secondary cataracts, particularly at the time of or following extracapsular extraction. "Preventing secondary cataracts" is intended to mean preventing growth of any residual lens epithelial cells on the lens capsule remnant after removal of a primary cataract by killing any residual lens epithelial cells present in the eye. The primary cataract can be of any type, including senile, juvenile and radiation-induced. "Treating secondary cataract" is intended to mean use of the device to inhibit proliferation of, preferably to kill, lens epithelial cells which have grown across the optic axis of the posterior lens capsule following removal of the primary cataract.

15 Treating and/or preventing secondary cataract relies on the introduction of an intraocular device into the posterior or anterior chamber of the eye, wherein the intraocular device comprises a polymer or macromolecule and at least one cytotoxic agent capable of selectively inhibiting proliferation of and/or killing any remnant lens epithelial cells present in the posterior chamber. The cytotoxic agent is dispersed in the macromolecule, particularly reversibly associated to or physically entrapped in the polymer, where the polymer optionally is cross-linked to form a matrix as a means of decreasing the rate of release of the cytotoxic agent from association with the macromolecule. In use, the device thus limits diffusion of the cytotoxic agent

20
25
30
35

6.

both temporally and spatially. The purpose of the described invention is to prolong the exposure time of any remnant of lens epithelial cells present in the posterior chamber to therapeutic concentrations of cytotoxic agent.

The intraocular device may be provided in several forms. It may be provided as a stand-alone device which can be used alone or in conjunction with other devices such as IOLs. It may be provided coated onto a support. It may be provided as components for bonding onto a support, for example, an IOL. Where the polymer itself is rigid enough to act as its own support, for example, crystalline, rubbery PEO-based hydrogels that are mechanically strong but not brittle, the polymer may be cast into a form for use, in conjunction with an IOL, where the form of the intraocular device is, for example, a circular ("O") ring or a donut capable of fitting around an IOL or to fit in the lens capsule with an IOL. The device is prepared having the diameter of the lens. It is then be placed in the eye so as to go around the periphery of the capsule. After the device is in place, an IOL can then be inserted.

Semi-rigid to flexible polymers which are degradable by water, such as polyglycolic acid, polygalactin or polyglyconate may be used for preparing support structures such as O-rings. Once the structures are formed, they then may be treated or coated with the intraocular device, where the polymer of the device may be the same or different from the polymer used to prepare the desired structure. Where the polymeric device is coated onto an IOL, generally it is coated onto the entire IOL, but more usually, the polymeric device is coated onto the haptic portion or supporting loops of the IOL. Generally the IOL support is prepared from polymers such as polymethylmethacrylate or silicone.

7.

Various macromolecules may be used for preparing the intraocular device. Water soluble polymers may be used which may be mixed directly with the cytotoxic agent in solution. The water soluble polymers may also be treated with cross-linking agents prior to interaction with a cytotoxic agent. Water insoluble polymers may also find use, where the polymer may be hydrated in a solution of the cytotoxic agent.

The characteristics of the polymer will include the following. The polymer must be biologically inert and physiologically compatible with tissues in the eye, i.e., it must be a polymer which does not in and of itself induce an inflammatory response or affects the viability of cells in the eye tissue beyond that occurring as a result of the surgical procedure. For some applications it may be desirable to use a biodegradable polymer, i.e., one which is subject to hydrolysis or which is broken down by biochemical processes such as enzymatic action. Examples of such polymers are the polymers used in dissolving sutures, for example, polyglycolic acid, collagen and the like.

One of the aims of this invention is to provide a means for sustained release from the device of a cytotoxic agent in the posterior chamber of the eye, therefore the polymer should be one which provides for reversible association of the cytotoxic agent with the polymer. Polymers which provide this characteristic include those capable of forming matrices so as to physically entrap the cytotoxic agent. Such a polymer may additionally be able to be cross-linked so as to provide a matrix of varying porosity. By varying the porosity, the rate of diffusion of the cytotoxic agent may be varied. The polymer should be hydrophilic so that when it is dry it has the capacity to take up water and cytotoxic

8.

agent so as to form a hydrogel which finds particular use in those cases where the polymer is to be formed (cast) prior to interaction with the cytotoxic agent. Generally, the polymer must not inactivate or react with the cytotoxic agent, although in some applications, a weak electrostatic charge on the polymer may be useful for reversibly binding the cytotoxic agent to the polymer. Examples of compounds which may form gels upon hydration include sodium hyaluronate and chondroitin sulfate.

The polymeric device may be prepared in several ways depending upon the intended form and the particular polymer to be used, as well as the nature of the cytotoxic agent, e.g. whether it is a small molecule or a large molecule, and the best way to reversibly associate the agent with the polymer. For example, where the polymer is an insoluble polymer the cytotoxic agent can be associated with a polymer by hydrating the polymer in a solution of the cytotoxic agent. The resulting hydrated polymer may take, for example, the form of a gel or a more rigid form. Examples of such hydrophilic polymers include cross-linked polyethylene oxide (PEO) and other polymers cross-linked with multifunctional alcohols (polyethylene glycols) and diisocyanates.

Where it is desired to provide the intraocular device with a support, particularly where the combination of the polymer and the cytotoxic agent has insufficient rigidity to cast into a form suitable for use in the eye, the polymer, particularly dry polymer, may be mixed with the cytotoxic agent and coated onto a support material. The support material may be any material which is biocompatible with tissues in the eye such as, for example, a ring of collagen or polyglycolic acid for use with an IOL, or the intraocular device may be coated directly onto an IOL. Providing the

9.

intraocular device either in a stand-alone form or coated onto an existing support offers the advantage that the intraocular device may be used with existing prototypes of IOL.

5 The polymer in a water soluble intraocular device, such as a hydrogel, can use an IOL as a support, where the device is applied as a coating to the IOL. The coating may be applied in a single step as described above, where the polymer and the
10 cytotoxic agent are mixed prior to coating onto the IOL. Alternatively, the polymer may be bound either covalently or noncovalently to an IOL. The IOL with the polymer attached can then be dipped into a solution of the cytotoxic agent, which may then be
15 dried and stored until implantation in the eye, or used immediately for implantation. Particularly where the polymer is to be adhered to the IOL prior to interaction with the cytotoxic agent, the polymer may as necessary be altered chemically, so that it
20 may be reacted directly with the surface of the IOL to form covalent bonds to the IOL.

 The choice of a particular macromolecule will depend at least in part on the method of use of the intraocular device and its physical form. Thus,
25 where the intraocular device is to be used in conjunction with an IOL and has to be cast into a particular form, it will be desirable to use a polymer which is capable of being cast into the desired form. Examples of such polymers include
30 polymers capable of forming hydrogels and structural proteins such as collagen which can be cross-linked to form a rigid structure. Where the intraocular device comprises a coating to be applied to an IOL, the polymer is desirably one which will not affect
35 the optical properties of the IOL. Another desirable property of the polymer for some applications is the capability of adhering to the surface of an IOL.

The preferred characteristics of the polymer include capacity for noncovalently interacting with or entrapping the cytotoxic agent. This capability provides for a source of cytotoxic agent in the eye which is released slowly into the eye and which thereby serves to decrease degradation of the immunotoxin which may occur from exposure to fluids in the eye or to decrease the removal by normal ocular processes of the cytotoxic agent from the eye. The polymer may be soluble or insoluble and will be capable of absorbing the cytotoxic agent either chemically, e.g., by way of electrostatic charge, or physically, e.g., by capillary action and/or entrapment, without affecting its therapeutic properties, while serving to retain the cytotoxic agent at the site of introduction. The proteinaceous materials may be a proteinaceous material that is physiologically acceptable to the internal environment of the eye of the host, generally a human. The proteinaceous material may be an individual peptide, but generally is a combination of peptides or proteins, e.g., albumin or other proteins, or structural proteins such as collagen, where the protein or polypeptide is crosslinked to provide for the desired matrix structure.

Where proteinaceous, particularly collagenous, material is used for preparing the intraocular device, it may be derived from any mammalian host source, such as bovine, porcine or human, or may be prepared, as available, by other techniques, e.g., recombinant DNA techniques. The collagen employed may be natural collagen or may be modified, such as tropocollagen, atropocollagen, or the like. The collagen may be nonimmunogenic, immunogenic, or only slightly immunogenic. Various methods for preparing collagen or derivatives thereof in purified form for administration to a mammalian host are known in the

11.

literature. These methods may be found in such patents as U.S. Patent No. 3,949,073 and references cited therein. Of interest is bovine collagen which is purified and is obtained from young cows or calves. Purification will normally involve dispersion or precipitation from various media, e.g., dilute acetic acid.

In addition, the cytotoxic agents can be employed encapsulated in liposomes or other controlled rate release compositions, which are included in the polymeric material, so as to provide for separate and distinct rates of release of the cytotoxic agents. In this way, multiphasic compositions can be prepared, so as to provide for sustained release of the cytotoxic agent over long periods of time. Formation of liposomes with inclusion of various materials is described in Papahadjopoulos (1978) Annals of the N.Y. Academy of Sciences, 308; Gregoriadis and Allison (1980) Liposomes in Biological Systems (John Wiley and Sons); Leserman et al., Nature (1981) 293:226-228; Barhet et al., Supramol. Struct. Cell Bio. Chem. (1981) 16:243-258; and Heath et al., Science (1980) 255:8015-8018.

When used with cytotoxic agents lacking specificity for epithelial cells, the liposomes themselves could be retained in the eye by, for example, coupling the glycoprotein streptavidin to the liposome as a biochemical linker. See, for example, U.S. Patent 4,885,172. Monoclonal antibodies or IgG capable of binding specifically to epithelial cells can be coupled to the streptavidin. Following introduction into the eye, the liposomes bind specifically to lens epithelial cells. Other methods of encapsulation also can be employed where the cytotoxic agent is encapsulated in a

12.

biodegradable coat and the rate of release is related to the thickness of the biodegradable coat.

5 The cytotoxic agent generally is a conjugate of a protein macromolecule capable of binding at least substantially specifically to epithelial cells, particularly lens epithelial cells, as compared to other cells which may be present in or in contact with the anterior or posterior chamber of the eye. For the most part, the cytotoxic compositions will be
10 conjugates of a monoclonal antibody or its equivalent with a cytotoxic agent. However, where the monoclonal antibody or its equivalent has the capacity to fix complement, the monoclonal antibody alone may be used. The monoclonal antibody may be
15 toxic by combination with either endogenous complement, or as appropriate complement may be injected subsequent to introduction of the monoclonal antibody into the anterior or posterior chamber of the eye.

20 The monoclonal antibody may be produced as a result of hybridoma formation and expression by the hybridoma, whether in culture or present as ascites, a monoclonal antibody fragment, such as Fab, F(ab')₂, Fv, a recombinant variable region, a T-cell receptor, or the like. The monoclonal antibodies and receptors
25 may be any mammalian species, including murine, rabbit, human or the like, or combinations thereof, such as chimeric antibodies, having a human constant region and a mouse or other mammalian source variable region. The antibodies may be any class or subclass, such as IgA, IgD, IgG, IgM, and may include IgG1, 2a, 2b, or 3 or the human equivalents thereof. The
30 monoclonal antibodies may be derived either from a simple hybridoma cell line or may be a mixture or "cocktail" of two or more monoclonal antibodies
35 derived from different hybridoma cell lines, where

13.

the antibodies would bind to the same or different antigenic moieties as the epithelial cells.

5 The methods for preparing the monoclonal antibodies are well established as evidenced by the numerous references described above (see "Relevant Literature"). An animal is hyperimmunized with a suitable immunogen, with or without addition of adjuvant. Various epithelial cells may be used as the immunogen, particularly human epithelial cells, 10 including tumor cells originating from epithelial cells, for example HeLa cells, although other species may find use, e.g., primates. Whole cells are preferred, however homogenates, membrane fragments or the like, can be used. The source of the cells 15 includes cells in tissue culture, surgical specimens such as tissues removed during cataract surgery, biopsy specimens, and the like.

 In accordance with the subject invention, a mammal, which can be a mouse or other small mammal, 20 is hyperimmunized with the immunogen. Methods of immunization are well known and are amply described in the literature. The immunogenic material, generally about 10^5 to about 10^6 cells or cell equivalents, is injected with or without adjuvant 25 into the mammal, or by repeated injections over relatively short periods of time. To ensure the hyperimmunization of the animal, 2-6 subsequent booster injections are administered. The animals are then killed, usually within 1-5 days after the last 30 injection, when it has been determined that a suitable titer of antibody has been obtained. Antibody-producing cells such as spleen cells or lymphocytes from the immunized animal are removed and immortalized.

35 The method of cell fusion is not a critical portion of this invention and various techniques may be employed. Generally a nonanoic detergent, for

14.

example polyethyleneglycol (PEG), is used as the fusigen. The antibody-producing cells, for example spleen cells and myeloma cells are combined in the presence of a known ionic detergent conveniently PEG1540 and other additives, for example, serum-free Dulbeccos modified Eagle's medium (SF-DMEM) for approximately 5 minutes. The excess nonanoic detergent is then rapidly removed by washing the cells. The cells are promptly dispensed into small culture wells at a relatively low density, ranging from about 1×10^5 /well to about 5×10^5 /well in appropriate medium, commonly a selective medium comprising hypoxanthine, and aminopterin and thymidine (HAT) medium.

After a sufficient period, usually one to two weeks, colonies of hybrids are observed. The colonies are then screened for antibodies which bind at least substantially specifically to epithelial cells. Once colonies producing the desired antibodies have been identified, the colonies may be perpetuated to provide for a continual source of the desired antibodies.

To identify hybridomas of interest, antibodies secreted by the immortalized cells are screened to identify the clones that secrete antibodies of the desired specificity. Screening of the hybridoma clones may be by binding to epithelial cells, particularly lens epithelial cells, using an ELISA assay. Other screening methods include radioimmunoassay and immunohistochemical staining of cryostat sections of ocular tissue. Furthermore, the resulting monoclonal antibodies may be isolated and modified by truncating the constant region by various peptidase digestions. The monoclonal antibodies may be reduced to provide for Fab fragments with available mercaptan sites for conjugation to other

15.

compositions. T-cell receptors may be obtained as described in W085/03947.

To obtain hybridoma cell lines secreting monoclonal antibodies directed to a single antigenic determinant associated with epithelial cells, the hybridoma cells may be cloned using, for example, limiting dilution. The stage at which the cells may be cloned is not critical to the invention, and may be before identification of colonies secreting antibodies of interest, or later. However, to avoid overgrowth of antibody producing cells with non-antibody producing cells, the colonies are preferably cloned as soon after fusion as practicable.

For large-scale production of antibodies, the hybridomas may be introduced into the peritoneal cavity of a mouse or other mammal and grown as ascites tumors. Antibodies may then be isolated from the ascites fluid. Alternate methods for large-scale production of monoclonal antibodies including introducing subcutaneous tumors using the method described and collecting blood from the animal. The hybridoma cells can also be grown on a large-scale in tissue culture. Where the cells secrete the antibodies into the growth medium, the conditioned growth medium containing the antibodies can be collected for antibody isolation. Where the hybridoma cells do not secrete the antibodies, the cells may be collected, lysed using conventional means, and antibody purified from the cell lysate. Methods of purifying monoclonal antibodies are well known to those skilled in the art.

The binding compositions having specificity for epithelial cells, may be joined to a wide variety of toxic agents which may be derived from microorganism or plant sources. Of particular interest are the toxic subunits of naturally occurring toxins, such as ricin, abrin, diphtheria toxin, etc. See for example

16.

Oeltmann and Heath, J. Biol. Chem. (1979) 254:1022-1027; Yule and Neville Jr., Proc. Natl. Acad. Sci. USA (1980) 77:5483-5486; Gilliland et al., Proc. Natl. Acad. Sci. USA (1978) 75:5319-5323; U.S. Patent No. 4,379,145; GB2034324 and Masuho et al., Biochem. Biophys. Res. Commun. (1979) 90:320-326; and Blythman, Nature (1981) 290:145, the relevant disclosures of which are incorporated herein by reference.

10 Illustrative toxin A-chains or similarly effective moieties include diphtheria toxin A-chains, enzymatically active proteolytic fragments from Pseudomonas aeruginosa exotoxin-A, ricin A-chain, abrin A-chain, modeccin A-chain, and proteins found
15 in various plants having similar activity, such as the plants Gelonium multiflorum, Phytolacca americana, Croton tiglium, Jatropha curcas, Momordic charantia, wheat germ, the toxin saponin from Saponaria officinalis (Thorpe et al., J. Natl. Cancer Inst. (1985) 75:151), Chinese cucumber toxin
20 Trichosanthin (McGrath et al., Proc Nat Acad Sci (USA) (1989) 86:2844-2848). Of particular interest is ricin A-chain. Also, mutant species of the toxins of the species may be used, such as CRM45 (Boquet et al., Proc. Natl. Acad. Sci. USA (1976) 73:4449-4453).
25

The toxic agents and moiety providing for binding to the epithelial cells may be linked, usually by a bond which is cleavable cytoplasmically. Convenient linkages include disulfide, particularly
30 where the toxic agent has an intrinsic sulfur, or other links, such as peptide links, urea links, thioethers, imines, amides, imides, amidines, etc. Functional groups which may find employment include carboxylic acid groups, amino groups, imines,
35 aldehydes, isocyanates, mercaptans, olefins, or the like. In addition, more complex linking groups can be employed, where a group may be bound to one of the

17.

moieties in the conjugate to provide for convenient linkage to an intrinsic group of the other moiety. For example, the N-hydroxysuccinimide ester of m-maleimidoylbenzoic acid may be employed to prepare an amide of the toxin, which may then be linked through an available sulfur atom on the monoclonal antibody to provide a thioether.

Exemplary cytotoxic agents may have the following formula:



wherein:

AS_n indicates the toxic agent having one or more sulfur groups as part of the agent; n is 1 or up to the number of sulfur groups present in the toxic agent which are present as available mercaptide groups, generally being up to about 4; R is a monoclonal antibody, T-cell receptor or derivative thereof; and m is 1 up to n, usually being from 1 to 2; and X is a linking group and may be a bond or a group of from about 1 to 20, usually 1 to 12 atoms other than hydrogen, which include carbon, nitrogen, oxygen and sulfur. Sulfur will normally be bonded to carbon, particularly aliphatically saturated. X may be aliphatic, alicyclic, aromatic, heterocyclic or combinations thereof, generally having from 0 to 6, more usually from about 0 to 4, preferably about 1 to 4 heteroatoms, wherein oxygen and sulfur are present as oxo or non-oxo-carbonyl or the thio analogs thereof, or ether (including thioether), and nitrogen is present as amino or amido. For the most part the heteroatoms will be bonded solely to carbon.

Illustrative groups linking the disulfide include aminoethylene 3-propanyl methylene carbonyl, α -succinimidyl, 3-propylenethiocarbonyl. The groups which may be used are for the most part conventional groups providing for a disulfide linkage. The disulfide compound is one which is capable of

18.

reacting with the cell-specific ligand, whereby a mercaptide group may be displaced from the disulfide, resulting in a new disulfide linkage between the toxic agent and the ligand.

5 For the most part, the linkages will be aliphatic of from about 1 to 6 carbon atoms, providing for an amide bond to the receptor, although this is primarily a matter of convenience, not necessary to the operability of the subject
10 compositions.

The cytotoxic agent can be prepared as a fusion toxin by expression of a recombinant DNA sequence encoding the cytotoxic agent. The required recombinant DNA sequence is constructed by isolating
15 a macromolecule having the desired target cell specificity (specificity domain) and ligating it to a protein toxin gene (cytotoxic gene).

The specificity domain and cytotoxic domain in general comprise portions of a single polypeptide
20 chain. The fusion toxin chain may be represented by the formula:



where Sp indicates the specificity domain; Jp
25 indicates at least one peptide bond, optionally including a peptide sequence, joining the specificity and cytotoxic domains; and Ct indicates the cytotoxic domain, i.e., the peptide backbone of the specificity domain is joined to the peptide backbone of the
30 cytotoxic domain through Jp. In its simplest form, where Jp constitutes a single peptide bond, the fusion toxin by the following structure:



where X-NH-CHR_n-CO- is the C-terminal nth amino acid
35 residue of domain X and NH-CHR₁-CO-Y is the N-terminal 1st amino acid residue of domain Y. Alternatively, Jp can be a joining peptide of arbitrary sequence and

19.

length which joins the peptide backbones of the specificity and cytotoxic domains through the peptide backbone of Jp, with the C-terminus of Jp joined by a peptide bond to the N-terminus of domain Y and the N-terminus of Jp joined by a peptide bond to the C-terminus of domain X. Jp may be cleavable to allow release of the toxin from the specificity domain. In either case, the two domains are joined through at least one peptide bond to make a single polypeptide chain.

Although in many embodiments Sp comprises the N-terminal end of the polypeptide, analogous to the arrangement of natural antibodies, immunotoxins can be created with Ct at the N-terminus. The specificity and cytotoxic functions are mediated by independent domains which in general are little affected by the presence of the other. In rare cases in which a particular fusion toxin functions significantly less efficiently than the sum of the constituent domains, steric hindrance is the probable cause, and can be remedied by increasing the length of the Jp or by reversing the order of the domains.

Fusion toxins are prepared by expression of a recombinant DNA sequence encoding the polypeptide. The required recombinant DNA sequence may be constructed by the steps of: isolating cDNA encoding the light and heavy chain genes of the monoclonal antibody exhibiting the desired specificity for epithelial cells from the corresponding hybridoma; isolating cDNA encoding a desired protein toxin; isolating the appropriate fragment of DNA from the heavy and light chain genes; ligating the two V_H and V_L encoding fragments in the same orientation and in-frame through a DNA region encoding a joining peptide as described in the definition of Jp to form the specificity domain Sp; and ligating, in-frame, the gene encoding the toxin to the gene encoding the

20.

specificity domain, optionally through a DNA encoding a joining peptide described in the definition of Jp.

5 An expression vector comprising the ligated DNA is then constructed and used to transfect a host organism which is then grown to express the fusion toxin. If a secretory leader sequence has been provided in the expression construct, the fusion toxin can be isolated from the growth medium and purified. Alternatively, where secretion is not
10 provided for, the cells can be lysed using methods known to those skilled in the art and purified so as to be substantially free of other cellular components.

15 In the first step for constructing the DNA sequence encoding the specificity domain, a monoclonal antibody capable of binding at least substantially specifically to epithelial cells is obtained as a result of conventional hybridoma formation, expression, and screening, or as a result
20 of making antibody fragments using phage display libraries (Huse et al., Science 246:1275, 1989; Clackson et al., Nature 352:624-628, 1991; Soderlind et al., Immunological reviews 130:109, 1992). The monoclonal antibodies and receptors can be of any
25 mammalian species, including murine, rabbit, human or the like. The antibodies can be of any class or subclass, such as IgA, IgD, IgG, IgM, and can include human subclasses IgG1, 2, 3, or 4, mouse IgG1, 2a, 2b, or 3, or the equivalents thereof in other
30 species; see Roitt et al., "Immunology," (2nd ed., 1989), Ch. 5. In preferred embodiments, most or even all of the constant regions of the source antibody are deleted from the fusion construct; consequently the class and subclass of the source antibody are of
35 little importance.

Methods for preparing monoclonal antibodies are well established as evidenced by numerous references

21.

in the scientific literature. An animal is hyperimmunized with a suitable immunogen, with or without addition of adjuvant. Various epithelial cells can be used as the immunogen, particularly human epithelial cells, including tumor cells originating from epithelial cells, for example ME180 cells. Cells from other species also can be used, e.g., primates. Whole cells are preferred, however homogenates, membrane fragments or the like, can be used. The source of the cells includes cells in tissue culture, biopsy specimens, and the like. Antibody-producing cells such as those from the spleen of the immunized animal, are removed and immortalized, typically by cell fusion with an immortal cell line, to produce a hybridoma. Alternative means of lymphocyte immortalization, such as transformation with an immortalizing virus, e.g. Epstein-Barr virus, are also possible. For convenience, all immortalized monoclonal antibody producing cells regardless of method of immortalization are referred to hereinafter as hybridomas.

To identify hybridomas producing monoclonal antibodies of interest, antibodies secreted by the immortalized cells, whether in culture or in ascites fluid, are screened to identify the clones that secrete antibodies of the desired characteristics. The most important characteristic of such antibodies is "substantially specific" binding to lens epithelial cells, i.e., the ability of the antibody to bind to lens epithelial cells at concentrations at which its binding to other structures within the posterior or anterior chambers of the eye is negligible. Preferably the amount of antibody bound per unit area to other cell types within the eye will be less than 5%, more preferably less than 2%, of the amount of antibody that is bound to lens epithelial

22.

cells. A second desirable characteristic of such antibodies is high affinity binding to the epithelial cell antigen. High affinity preferably means a dissociation constant (K_d) of 10^{-7} M or less.

5 Screening of the hybridoma clones can be performed by binding to epithelial cells, particularly lens epithelial cells, using an ELISA assay. Other screening methods include radioimmunoassay and immunohistochemical staining of cryostat sections of
10 ocular tissue.

After a hybridoma producing a monoclonal antibody having appropriate specificity for epithelial cells is identified, cDNA encoding the antibody is isolated from the corresponding
15 hybridoma. This is accomplished by preparing cDNA from messenger RNA (mRNA) obtained from hybridoma cells by conventional means, followed by ligation of the cDNA into phage λ to produce an expression library. The preferred vector is lambda ZAP II from
20 Stratagene (La Jolla, CA), although other variants can be used. The ligation mixture is packaged by conventional means and used to transfect *E. coli*. The preferred strain of *E. coli* is XL1-Blue from Stratagene, although other strains can also be used,
25 for example Y1090r- (*Molecular Cloning, A Laboratory Manual*, Sambrook, J., et al., Cold Spring Harbor Laboratory Press, Plainview, NY). The infected bacteria are plated out on agar plates so that isolated plaques are observed.

30 Expression of light and heavy chain antibody genes is determined by immunoblot screening of the plaques. The preferred antibodies used to screen the λ library bind to the constant regions of either the heavy or light chain of the mouse monoclonal antibody
35 and are conjugated to alkaline phosphatase or peroxidase so that a color development reaction can be used to detect the plaques to which they bind.

23.

Several plaques can be isolated to ensure that the heavy chain and light chain genes are represented. Those plaques which express antibody genes are purified by reinfection followed by screening, as described above, until a homogeneous preparation of phage is obtained from each of the original plaques.

The homogenous λ lysogen culture is coinfecting with a helper phage, preferably M13K07. The coinfecting culture yields M13 transducing phage containing single stranded plasmid which harbors a gene encoding either V_H or V_L .

The transducing phage containing lysate is isolated by conventional methods and used to reinfect a culture of XL1-Blue. These cultures are used to stably maintain the cloned genes encoding the heavy and light chain on a plasmid vector. These plasmids are isolated and sequenced to confirm the identity of the genes as described below.

The genes encoding the desired variable regions of the light and heavy chains can also be cloned using the polymerase chain reaction. Specific primers are used in conjunction with a preparation of cDNA isolated from the hybridoma to amplify a region of the cDNA that encodes the V_H and V_L . These amplified DNA fragments are then cloned into plasmid vectors

The structure of a typical IgG antibody is shown in schematic form in Figure 3 with the variable regions of the heavy and light chains as indicated. The variable regions in turn contain alternating framework (FR) and complementarity-determining (CDR) regions. In each chain, four FRs bracket three CDRs. The CDRs provide the surfaces which interact directly with antigen, while the FRs position the CDRs adjacent to each other in proper tertiary conformation. CDRs have variable sequences for antibodies of

24.

different specificities, whereas the FRs are more conserved for a given antibody type and species.

Primers for PCR amplification of the heavy and light chain variable regions are chosen to bind to the 5' and 3' ends of the respective variable regions. Primers for the 3' ends of the sequence encoding the light chain and heavy chain variable regions (V_L and V_H , respectively) are readily obtained from the sequences encoding adjacent light chain and heavy chain constant domains.

The 5' primers can be obtained in several ways. First, the heavy and light chain N-termini of a particular monoclonal antibody having the desired characteristics are partially sequenced for 6-10 amino acids, and a DNA primer is synthesized based upon the corresponding deduced nucleotide sequence(s). Alternatively, a primer is designed corresponding to relatively conserved leader sequences or first framework region (FR_1) sequences of the heavy and light chains characteristic of the hybridoma source species.

The appropriate sets of primers are used to amplify the cDNAs which encode the variable regions of the light and heavy chains (See Chaudhury (1989); Pluckthun, *Bio/Technology* (1991) 9:545; Larrick et al., *Bio/Technology* (1989) 7:934.) The amplified V_L and V_H DNA fragments are purified by conventional techniques such as agarose gel electrophoresis on low melting agarose and cloned into plasmid vectors.

Several copies, generally at least three independently isolated copies, of the variable region heavy and light chain encoding DNA fragments sequenced to ensure that the variable regions contain the expected three complementarity determining regions (CDR1, CDR2, and CDR3) bracketed by four framework regions (FR1, FR2, FR3, and FR4). The variable framework regions can be abbreviated or

25.

modified, including humanized. Isolated heavy or light chain variable domains have selective binding affinity for their target antigens even without the presence of the complementary chain. (See Ward, 5 *Nature* (1989) 341:544.)

Although V_L and V_H peptides are capable of binding independently to antigen and either could be used alone as the specificity domain, the combination of both creates a single chain specificity domain of 10 greater affinity and selectivity and is preferred. Appropriate DNA sequences encoding the V_L and V_H are joined in-frame, preferably through a DNA sequence encoding a "linker" region comprising one or more peptide linkages, to make a DNA sequence encoding a 15 single chain specificity domain. Necessarily the single polypeptide produced by expression of the above DNA coding region has its composite domains joined through peptide linkages or bonds. Specificity domains of this structure will correspond 20 to the general formula:

$$V_H'-Li-V_L'(3)$$

where Li indicates the linker region and V_L' and V_H' indicate light and heavy chain variable domains, respectively; the primes indicate that the variable 25 regions can be substantially modified from the sequence of the parent antibody, especially in the FRs.

Either V_L or V_H can provide the N-terminus of the epithelial cell specific antigen binding or 30 "specificity" domain. The intervening linker region can be of arbitrary length and sequence, but should be of sufficient length to permit the V_L and V_H polypeptides to interact correctly and provide for an appropriate tertiary structure. The distance between 35 the C-terminus of V_L and the N terminus of V_H has been reported to span 3.7 nm; see Whitlow and Filpula, "Single Chain F_V Proteins and/or Fusion Proteins," in

26.

Methods: A Companion to Methods in Enzymology (1991).
Linkers of 10-30 amino acid residues are preferred,
with those of 14-25 amino acid residues being more
preferable. Flexible linkers also are preferred;
5 these may be designed using small soluble amino acids
such as alternating glycine and serine residues. At
a few positions along the linker, charged residues
also can be introduced to enhance water solubility of
the linker, since the N-terminal and C-terminal ends
10 of the variable regions to be linked in general are
solvent accessible. See Chaudhury, *supra*; Sastry et
al., *Proc. Natl. Acad. Sci. USA* (1989) 86:5728-5732.

The specificity domain is cloned into an
expression vector to permit testing of the resulting
15 polypeptide for binding affinity and specificity.
Expression of functional specificity domains is
accomplished from bacterial hosts such as *E. coli*, or
from eukaryotic hosts including yeasts, insect cells,
or mammalian cells. Naturally, an appropriate
20 expression vector is matched to the anticipated host
cells. An appropriate expression vector comprises a
promoter capable of providing transcription in the
host species, transcriptional and translational start
sequences, optionally a signal sequence to provide
25 for secretion, the V_L and V_H coding sequences joined
by a linker region, and translation and transcription
termination sequences. Optionally, DNA encoding
portions of the heavy and light chain constant
regions may be included at the 3' ends of the V_L
30 and/or V_H coding regions. The resulting expression
vector is used to transform the appropriate host cell
and obtain expression of the specificity domain. The
expressed epithelial cell binding or specificity
domain polypeptides are then screened to identify
35 clones exhibiting lens epithelial cell specific
binding. Screening for the specificity domain
polypeptides is performed essentially as described

27.

supra for monoclonal antibodies. It generally is performed by radioimmunoassay or by competition with parent monoclonal antibody binding in an ELISA assay.

5 The specificity domains of polypeptides of the present invention are not restricted to domain sequences which are identical to those of the source monoclonal antibodies. In particular, the term "specificity domain" of the present invention encompasses an epithelial cell binding domain which
10 is homologous to the variable region of an antibody heavy or light chain.

Other toxic agents may also be used, such as bismuth non-diffusively linked to the monoclonal antibodies or receptors as described by Waldman, J. Amer. Med. Assoc.
15

Alternatively, liposomes may be linked to the monoclonal antibodies or receptors, where the liposomes contain various cytotoxic agents, such as methotrexate, 5-fluorouracil, any of the above
20 toxins, or the like. See, for example, Szoka and Papahadjopoulos, Proc. Natl. Acad. Sci. USA (1978) 75:4194-4198 and Szoka et al., Biochem. et Biophys. Acta. (1980) 601:559-571 for the preparation of liposomes, which disclosures are incorporated herein
25 by reference. Linking of antibodies to the liposomes has been amply described in the literature, see for example Heath et al., Proc. Natl. Acad. Sci. USA (1983) 80:1377-1381 and Leserman et al., Nature (1981) 293:226-228, which disclosures are incor-
30 porated herein by reference.

Other cytotoxic agents conjugated to the binding moiety may also be employed in conjunction with the process of this invention. The cytotoxic agent can be used with other agents such as lysomotropic
35 amines, carboxylic ionophores and calmodulin inhibitors. Examples include ammonium chloride, methylamine, chloroquine, monensin or verapamil. For

28.

descriptions of these agents, see, for example, Casellas et al., Immunotoxin (1988) Kluwer Academic Publishers; Myers et al., Blood (1984) 63:1178-1184; Casellas, J. Biol. Chem. (1984) 259:9359-9364; and
5 Akiyama, J. Cell Physiol. (1984) 120:271-279.

The intraocular device comprising the polymer and the cytotoxic agent may be used *in vivo*, by introduction directly into the posterior chamber of the eye so as to provide for a higher concentration
10 of the immunotoxin in the immediate vicinity of the posterior chamber and the lens capsule and remnant lens epithelial cells than in surrounding structures. The amount of the immunotoxin released from the intraocular device in a given period of time can be
15 varied, depending upon the total amount of cytotoxic agent associated with the intraocular device and by the composition of the polymer, for example, the concentration of polymer, the viscosity, and the like.

For example, to decrease the rate of release, the polymer may be cross-linked so that diffusion is controlled by the size of the cytotoxic agent, or the polymer may contain a slight charge, so that the attraction between the polymer and the cytotoxic
20 agent is more than simple diffusion into the polymer but does not constitute covalent bonding to the polymer.

The amount of cytotoxic agent associated with the intraocular device is of an amount sufficient to
30 kill at least substantially all of the remnant lens epithelial cells in the eye following release from the device. Generally a total amount of between 0.1 to 20 μg , more usually 0.5 to 10 μg , preferably 1.0 to 5 μg is associated with the intraocular device.
35 The amount of release of immunotoxin from the intraocular device is usually from about 10-25% for the initial hour of release, and reaches a steady

29.

state of amount of release of about 10% to 20% per hour thereafter.

The intraocular device may comprise a single cytotoxic agent reversibly associated with a polymer or it may comprise more than one cytotoxic agent. Other cytotoxic agents and/or antiproliferative drugs which may be used include methotrexate and daunorubicin. See, for example, Shawler et al., J. Biol. Resp. Mod. (1988) 7:608-618; Dillman et al., Cancer Res. (1988) 48:6097-6102. To provide the necessary specificity of action, the cytotoxic agents are preferably bound to an antibody, generally a monoclonal antibody, capable of binding at least substantially specifically to epithelial cells.

The intraocular device can be prepared by combining the various components in a sterile environment. The polymer and the cytotoxic agent can be provided in a convenient form, usually in the form of a solution, although in some instances the polymer may be provided as a solid, which is then coated with the cytotoxic agent directly, or which is coated with a polymer/cytotoxic agent dispersion. Preferably, the intraocular device is provided with an IOL support, the intraocular device being coated onto the surface of the lens so as to provide for ease of introduction into the posterior chamber or lens capsule. The intraocular device either with or without an IOL support, should fit inside the lens capsule for fixation in the ciliary sulcus and/or other parts of the eye wall with or without sutures. The intraocular device could also be placed in the anterior chamber when there is no or little lens capsule left, so that the immunotoxin could diffuse into the posterior chamber.

When the polymer comprises collagen or a derivative thereof, the collagenous material will normally be provided as a uniform dispersion of

30.

collagen fibers in solution. The cytotoxic agent may then be added to the collagenous dispersion with agitation to ensure the uniform dispersion of the cytotoxic agent in the resulting mixture. The amount of cytotoxic agent associated with the polymer will be sufficient to substantially completely or completely kill all of the lens epithelial cells following release from the polymer. Other materials, as appropriate, may be added concomitantly or sequentially. After ensuring the uniform dispersion of the various components in the mixture, the mixture may be sterilized by any means which will not interfere with the biological activity of the antiproliferative or other agents and sealed in an appropriate container. Preferably, sterilization will be achieved by using aseptic techniques and aseptic conditions to admix already sterile components.

In addition to the major components, a number of minor components may also be included for a variety of purposes. These agents will for the most part impart properties which protect the stability of the composition, control the pH, or the like, such as stabilizers including sugars, wetting agents, etc. Illustrative agents include phosphate or acetate buffers, methyl or propylparaben, polyethylene glycols, etc. These agents generally will be present in less than about 2 weight percent of the total composition, usually less than about 1 weight percent, and individually may vary from about 0.001 weight percent to about 1 weight percent.

As already indicated, in some instances the immunotoxin will be encapsulated, particularly in liposomes. Liposomes are prepared from a variety of lamellar-forming lipids including phospholipids, e.g., phosphatidylcholine, phosphatidylethanolamine,

31.

etc., gangliosides, sphingomyelins, steroids, e.g., cholesterol, etc.

Where the cytotoxic agent is a combination of monoclonal antibody and complement (either endogenous and/or exogenous), the monoclonal antibody can be introduced as described above for the cytotoxic agent. If exogenous complement is to be used, it is introduced, generally after 30 to 60 mins., into the anterior chamber in an amount of from 25-200, more usually from about 50-150 μ l which agent will be present in an amount sufficient to substantially completely or completely kill all of the lens epithelial cells. The complement is a standard complement. By complement is intended normal serum of men or other vertebrates which comprises about 9 major proteins which react with antigen-antibody complexes to cause damage to cell membranes, and including lysis. A complement is usually supplied as serum, for example, rabbit serum. A typical complement and its preparation useful in the present invention is described in Monoclonal Antibodies (1980), Printing Press, New York Eds. Kennett, et al. pp. 391-392 which publication is incorporated herein by reference. Alternatively, it is possible to use patient complement activity which may be obtained in sufficient concentration from aqueous humor during surgery. The complement is prepared in an appropriate dilution of rabbit serum in a physiologically acceptable medium containing Mg^{2+} and Ca^{2+} .

Generally, the cytotoxic effect will be realized within a relatively short time after binding of the cytotoxic agent to the cells, generally 0.5-15 hrs, depending upon the concentration of cytotoxic agent used and the rate of release of the cytotoxic agent from the intraocular device. Binding itself will occur within a relatively short time, after the

32.

instillation of the intraocular device. Where the cytotoxic effect is realized by the combination of monoclonal antibody and complement, the cytolytic effect is realized within a relatively short time after the introduction of complement, usually in about 0.5 hr. - 1.0 hr; lysis of the target cells can be used to evaluate the onset of the cytolytic effect.

The development of secondary cataract can take from a few months to several years. Clinically, a secondary cataract is determined by slit lamp microscopy presenting as the appearance of lens epithelial cells growing on the posterior lens capsule. The invention described herein would allow for the prolonged release of therapeutic concentrations of lens epithelial cell specific cytotoxic agents that would destroy these cells and hence prevent their proliferation. Thus, slit lamp microscopy can be used to determine that development of a secondary cataract has not occurred. In cases where a secondary cataract does occur, either subsequent to treatment with the intraocular device, or in the absence of treatment, the intraocular device may be introduced into the anterior or posterior chamber as previously described for use at the time of cataract surgery for removal of a primary cataract.

The IOL may be provided already treated with the polymer in a form ready for reaction with the immunotoxin or as an IOL or other support coated with polymer and immunotoxin. Alternatively, the components for preparing the intraocular device are provided as lyophilized powders for reconstitution, as concentrated solutions, or ready for use. The subject compositions can be provided as kits for use in one or more operations. The kits will include the polymer and the cytotoxic agent in separate

33.

containers, either as concentrates (including lyophilized compositions), which may be further diluted prior to use in an appropriate diluent for use in the eye or at the concentration of use, where the containers can include one or more dosages. Conveniently, single dosages may be provided in sterile vials, so that the physician may employ the vials directly, where the vials have the desired amount and concentration of agents. Thus, the kit may have a plurality of vials containing the polymer as well as the cytotoxic agent in appropriate proportional amounts. Where the containers contain the formulation for direct use, usually there will be no need for other reagents for use with the method, although optionally the kit may include separate containers of complement for use with the IOL.

The following examples are offered by way of illustration and not by way of limitation.

20

EXPERIMENTAL

Preparation of monoclonal antibodies capable of binding at least substantially with lens epithelial cells and methods for preparing immunotoxins are provided for example in U.S. Patent No. 4,871,350 and references cited therein, which disclosures are hereby incorporated by reference. Monoclonal antibody-producing cell lines have been deposited with the ATCC Accession Number HB9747.

30

Example 1

Effect of polyoxypropylene - polyoxyethylene block polymer (Pluronic® F68) on antibody binding to ME180 cells

Monoclonal antibody 4197X at 2 mg/ml was mixed with F68 to obtain a final concentration of antibody of 1 mg/ml and 10, 5, 2, 1 and 0% F68. These solutions were incubated for 1 hr at 37°C followed by

34.

24 hrs at 4°C. Aliquots (100 µl) were removed after the 1 and 24 hr time points, and diluted to a final concentration of 10 µg/ml antibody in DMEM containing 10% FBS and a standard amount of ¹²⁵I-4197X.

5 ME180 cells (human cervix epithelial obtained from the ATCC) were grown to confluence in 96-well plates. The diluted antibody (200 µl) was then added to the culture plates containing the ME180 cells and evaluated for its capacity to competitively inhibit
10 the binding of ¹²⁵I-4197X to the ME180 cells. The wells were incubated for 1 hr at 37°C after which they were washed to remove unbound antibody. To determine cell-associated radioactivity, the cells were solubilized in 10% SDS (50 µl per well) and the
15 soluble extract harvested with a cotton-tipped applicator stick which was then counted in a gamma counter. Binding was compared to the cell-associated radioactivity in the absence of competing antibody. Preincubation of antibody with F68 had little effect
20 on its subsequent ability to bind to target cells.

Example 2

Determination of volume of F68 solution associated with an intraocular device (IOL)

25 Two solutions of F68 and ¹²⁵I-4197X antibody were prepared. One preparation contained 4197X-RA immunotoxin at a concentration of 50 µg/ml. The second preparation contained an equivalent volume of buffer instead of immunotoxin. The radioactivity in
30 1.0 ul of the immunotoxin preparation was determined to be 13,501 cpm. IOLs were immersed in these solutions and excess liquid allowed to drain off. The radioactivity associated with one of the IOLs was 48,438 cpm. The volume of F68 immunotoxin mixture
35 associated with the IOLs was calculated to be 3.6 µl.

35.

Example 3Evaluation of Release and Cytotoxicity
of Immunotoxin from Intraocular Device
Coated onto an IOL

5 The release of radioactivity from an intraocular
device coated onto an IOL, to cell culture medium is
shown in Table 1. Two solutions of F68, immunotoxin
and ¹²⁵I-antibody were prepared, as described above.
One preparation contained immunotoxin at a final
10 concentration of 50 ug/ml. The final concentration
of F68 was 10%. The other preparation contained an
equivalent volume of buffer instead of immunotoxin.
IOLs (sterilized by autoclaving) were immersed into
these solutions and excess liquid allowed to drain
15 off. The IOLs were allowed to dry for 2 hours at
room temperature (until tacky). The IOLs were then
placed in cell culture wells (24 well plate)
containing ME 180 cells (25% confluent) and 1.0 ml of
cell culture media containing 10% fetal bovine serum.
20 The cells were incubated (37°C, 5% CO₂) until control
wells reached confluence. At various times during
incubation, samples of culture supernatant (50 ul)
were removed and counted for radioactivity. At the
end of the incubation period, the wells were examined
25 microscopically for cell viability. Photographs were
taken of all wells for later verification of results.

 Viable cells were present in all wells not
containing immunotoxin. IOLs alone had no effect on
cell growth. There was a marked lack of cell growth
30 and cell viability in wells containing immunotoxin.
At 0.175 ug immunotoxin/IOL in 1.0 ml of cell culture
media and assuming all immunotoxin was released into
the media the effective concentration would be 0.175
ug/ml. The IC₅₀ of immunotoxin alone for continuous
35 exposure as used in this experiment is approximately
0.02 µg/ml.

Table 1
Release of ^{125}I -4197X from Intraocular Device
(Polymer = F68) Coated onto IOL Support

5	<u>Time¹</u>	<u>Total Released Radioactivity</u>
		<u>(cpm/well)</u>
	0	0
10	1	22,896
	3	35,485
	18	59,128
	72	62,223

15 ¹ Hours after introduction of IOL into cell culture.

Example 4

Determination of volume of F68 solution
and amount of immunotoxin associated with
a intraocular device after drying

20 Three solutions of F68, immunotoxin and ^{125}I -
immunotoxin (^{125}IT) were prepared. The radioactivity
in a specified volume (cpm/10ul) of each preparation
was determined. The three preparations had a final
25 concentration of 10% F68 and 0, 4 and 20 ug/ml of
immunotoxin. The final concentration of ^{125}I -
immunotoxin was the same in all three solutions and
determined to average 1,434 cpm/ μl . The immunotoxin
concentration of the labeled material was very low
30 and did not significantly contribute to the overall
immunotoxin concentration. IOLs were immersed (three
times at 2 minute intervals) in these solutions and
excess liquid allowed to drain off. The volume of
F68 associated with the IOLs was determined by
35 counting three of the IOLs in a gamma counter. The
results were an average of 8,915 cpm \pm 1812 cpm/IOL.
Using this number, it was calculated that IOLs
immersed in 4 ug/ml immunotoxin had 0.025 ug of

37.

associated immunotoxin/IOL and IOLs immersed in 20 ug/ml immunotoxin had 0.124 ug of associated immunotoxin/IOL.

5

Example 5Effect of Immunotoxin released from
intraocular devices on human lens
epithelial cells in vitro

10 The release of radioactivity from IOLs coated with the intraocular device to cell culture medium, is shown in Table 2 (below). Three solutions of F68, immunotoxin and ^{125}I -antibody was prepared as described above. IOLs (sterilized by autoclaving) were immersed into this solution and excess liquid
15 allowed to drain off. The IOLs were allowed to dry for 18 hours until dry. The IOLs were placed in cell culture wells (24 well plate) containing HLE cells (from cataract surgery capsule explants and maintained under tissue culture conditions) in 1.5 ml
20 of cell culture medium. The cells were incubated for 7 days. At various times (15 min., 60 min. and 24 hrs.), samples of culture supernatant (50 ul) was removed and counted. At the end of the incubation period, wells were examined microscopically for cell
25 viability. Photographs were taken of all wells. At the end of the observation period IOLs were removed, rinsed once in PBS, and counted. As indicated in Example 4, the initial average IOL-associated cpm was $8,915 \pm 1,812$. Following incubation in cell culture
30 medium, the average cpm associated with the IOL was 153 cpm which corresponds to a release of 98.3% of the radioactivity associated with the intraocular device.

35 Viable human lens cells were present in all wells not containing immunotoxin. IOLs alone had no effect on cell growth. There was a marked lack of cell growth and cell viability in wells containing

38.

immunotoxin. Cells exposed to IOLs coated with immunotoxin at 4 ug/ml (0.025 μ g/IOL) were partially affected. No viable cells were present in wells containing IOLs coated with immunotoxin at 20 ug/ml (0.124 μ g/IOL).

Table 2

Release of 125 I-4197X-RA from

Intraocular Device (polymer = F68)

Coated onto an IOL into Culture Supernatant

Time

Mean Total Released
Radioactivity^{1,2}/Well

	<u>in cpm</u>	<u>% Initial IOL associated radioactivity</u>
15 minutes	3,360	38
60 minutes	4,590	51
24 hours	10,890	122

¹Control = 297 cpm/IOL

²Initial IOL-associated radioactivity before being placed into cell culture = 8,915 \pm 1,812 cpm/IOL

Example 6

Examination of Various Polymers for Coating
IOLs with Immunotoxin

Plastic culture wells were used to simulate coating of IOLs. Immunotoxin (4197X-RA) was mixed with various polymers (See Table 3) and examined for cytotoxic activity following drying on to the plastic tissue culture wells. The simulated IOLs were prepared as follows. Polymer stock solutions were prepared in phosphate buffered saline (PBS) and sterilized by autoclaving. Equal portions of polymer and sterile immunotoxin (at 770 ug/ml) or polymer and PBS were mixed under sterile conditions and 20 ul of each of the resulting mixtures added to individual

39.

wells of a 24 well cell culture dish. The solutions were allowed to dry in a sterile hood with lids open at room temperature for 3 hours.

1.0 ml of cell culture media (M199 containing 10% fetal bovine serum) was added to simulated IOL to rehydrate the immunotoxin followed by gentle agitation for 30 minutes at room temperature. Following rehydration individual supernatants developed from simulated IOLs were assayed for cytotoxic activity against ME 180 cells using MTT Mosmann, *J. Immunol. Methods* (1983) 65:65 to measure the amount of cell proliferation. Immunotoxin diluted in PBS alone or in polymer without drying was also evaluated using the method described above. The effects on cell proliferation (expressed as percent inhibition of cell growth) for a simulated IOL containing about 0.24 ug/ml immunotoxin are shown in Table 3.

The simulated IOLs were prepared by combining immunotoxins with any of a variety of polymers and then drying them onto tissue culture plates for three hours, as described above. The majority of immunotoxin polymer mixtures were as active as untreated immunotoxin in PBS in inhibiting cell proliferation. Hydroxpropylmethylcellulose and polyvinylpyrrolidone were slightly more active; these polymers alone exhibited some antiproliferative activity (percent inhibition of cell growth 17.3 and 21.6 for the two polymers, respectively). All other polymers alone had little or no antiproliferative activity. Immunotoxin mixed with Pluronic F127 and Pluronic F68 antiproliferative lost activity as a result of drying. Immunotoxin in these polymers without drying gave percent inhibitions of 87.8 and 91.1 respectively. Immunotoxin in all other polymers without drying had essentially the same activity as immunotoxin in PBS.

Table 3

		<u>Percent Inhibition of Cell Growth</u>
5		Immunotoxin 4197X- RA in Polymer (dried 3 hours) ²
	<u>Polymer</u> ¹	
10	Methylcellulose (medium viscosity) 2% (Sigma Chemical Company)	84
	Carboxymethylcellulose (medium viscosity) 2% (Sigma Chemical Company)	83.1
15	Hydroxypropylmethylcellulose (low viscosity) 2% (Sigma Chemical Company)	88.7
	Hydroxypropylmethylcellulose (high viscosity) 2% (Sigma Chemical Company)	100
20	Polyvinylpyrrolidone (PVP-360) 5% (Sigma Chemical Company)	100
	Polyethylene Glycol 40% (Sigma Chemical Company)	76.2
25	Pluronic F127 20% BASF Corporation	42.8
	Pluronic F68 20% BASF Corporation	43.9
30	Methocel E4M 1% Dow Chemical Company	86.7
	Methocel E50LV 2% Dow Chemical Company	85.9
	Methocel E5 5% Dow Chemical Company	82.6
35	Methocel E15LV 5% Dow Chemical Company	82.0
	Polyvinyl alcohol 5% Aldrich Chemical Corp.	78.8

40

¹ The indicated % is the concentration of the polymer stock solution in PBS.

45

² 4197X-RA in PBS Control (not dried) resulted in 86.8% inhibition of cell growth.

41.

Example 7Release of 4197X-RAImmunotoxin from Intraocular Device Coated
Onto a Simulated IOL and Cytotoxicity

5

Polystyrene balls were used to simulate IOLs for this study. The immunotoxin used in these experiments was 4197X-RA. One part of immunotoxin was mixed with two parts Methocel E4M (1% in PBS) and one part maltose (1M). The release of radioactivity from immunotoxin-polymer coated polystyrene balls (1/4 inch diameter, Polysciences) over time is shown in Table 4. The release of cytotoxic activity from coated balls is shown in Table 5. Preparation of materials used in these experiments was performed with sterile reagents under sterile conditions.

10

15

20

25

30

35

In the experiment to determine rate of release of radioactivity from the simulated IOLs, the 4197X-RA was labeled with ¹²⁵iodine. Individual balls were dipped into the coating mixture and allowed to air dry for two hours at room temperature. The coated balls were then dipped into a 5% solution of Methocel E15LV and allowed to air dry for 2 hours. This step was repeated two more times. After the final dip in Methocel E15LV the coated balls were allowed to air dry at room temperature overnight. Individual immunotoxin coated balls were then immersed into 1 ml of PBS (for determination of radioactive release) or M199 containing 10% FBS (for determination of cytotoxic activity release). At specified times balls (3 per time period for radioactivity, 2 per period for cytotoxicity) were removed from incubation solutions. Ball-associated radioactivity was determined by placing the balls in a gamma counter.

42.

Table 4
Release of 125 -I-4197X-RA from Intraocular Device
(Polymer=Methocel E4M) Coated Onto A
Simulated IOL Support

5

<u>Time (Minutes)</u>	<u>Percent Released Radioactivity¹</u>
10	7.9
20	17.9
30	21.6
60	46.7
120	70.2

10

¹ Values are the mean of 3 determinations using 3 balls per time point.

15

Cytotoxic activity associated with the incubation solution was determined by titration of the solution and exposing the dilutions to ME 180 cells. An MTT assay was used to determine the percent inhibition of cellular proliferation.

20

Table 5
Release Of 4197X-RA Cytotoxicity From
Intraocular Device (Polymer=Methocel E4M)
Coated Onto A Simulated IOL Support

25

<u>Time (Minutes)</u>	<u>Percent Cytotoxic Activity Released¹</u>
10	3
20	25
30	42
60	50
120	100

30

35

¹ Values are the mean of 2 determinations using 2 balls per time point.

43.

Example 8Evaluation of Cytotoxicity of 3D4-RA Immunotoxin
Intraocular Device Coated Onto
an IOL Over Time

5

The release of cytotoxic activity of an immunotoxin (3D4-RA) from an intraocular device coated onto an IOL was evaluated. The following steps were performed with sterile reagents under sterile conditions. Immunotoxin 3D4-RA (1.56 mg/ml) was mixed with Methocel E4M and maltose as described in Example 7. Four polymethylmethacrylate (PMMA) intraocular lenses (Alcon) were dipped into the mixture. Two of the IOLs were allowed to dry and coated with Methocel E15LV as in Example 7 and the remaining two were immediately placed in 1 ml M199 containing 10% FBS and incubated for 6 hours at 4°C. After 24 hours the coated and dried IOLs were placed in M199 and incubated for 6 hours at 4°C?. Cytotoxic activity of the extracts was analyzed on ME 180 cells using MTT to determine inhibition of cellular proliferation as described in Examples 6 and 7. The cytotoxic activity extracted from IOLs coated with 3D4-RA in polymer and dried for 24 hours was the same as that extracted from IOLs coated but not dried (control).

10

15

20

25

44.

Example 9In Vivo Analysis of 3D4-RA Immunotoxin¹ Intraocular
Device Coated IOLs for the Prevention of
Secondary Cataract

5

Immunotoxin associated with an IOL would place the cytotoxic agent in immediate proximity with the target cell population and increase residence time of the immunotoxin and the cytotoxic agent in the eye. These factors could lead to a more efficacious killing of target lens epithelial cells. Secondary cataract typically develops in rabbits within a few weeks following cataract surgery as indicated by proliferation of residual lens epithelial cells on the posterior lens capsule. The effect of IOLs coated with a 3D4-RA immunotoxin intraocular device on proliferation of residual lens cells was evaluated in vivo in a rabbit model. In this study, a 3D4-RA immunotoxin device-coated IOL was used.

10
15
20

Four normal female white New Zealand rabbits were randomly assigned to two treatment groups: (1) control group, and (2) immunotoxin treatment group. Both groups underwent lens extraction surgery with phacoemulsification in one eye. The surgical procedure simulated the method used on humans to remove primary cataracts. Group 1 received untreated lenses, group 2 received lenses treated with a polymer coating containing immunotoxin as described in Example 8.

25

30

All of the rabbits received one week of standard post-surgical care involving anti-inflammatory (topical steroid and antibiotic (topical gentamicin)

35

¹ 4197X does not bind rabbit lens epithelial cells, an immunotoxin was constructed using a different monoclonal antibody, 3D4. This antibody, while being less specific than 4197X, does bind rabbit lens epithelial cells and kills these cells *in vitro* when coupled to ricin A.

45.

treatment. The animals were observed for four weeks after surgery. At four weeks all animals were sacrificed and their eyes were collected. None of the animals exhibited gross toxicological or pathological reactivities to the implanted lenses.

Eyes were processed for histology, embedded into parafin and cut into thin sections, individual sections were stained and examined microscopically. The microscopic evaluation of the explanted eye sections revealed that the control eyes containing the untreated lenses exhibited epithelial cell growth on anterior and posterior walls of the lens capsule, i.e., development of secondary cataract. Deeper sections showed substantial epithelial cell piling on the anterior wall with a single layer of epithelial cells present on the posterior capsule wall with additional piling of cells at the equatorial regions.

The examination of sections from eyes containing the immunotoxin-treated lenses revealed little or no cellular growth on the lens capsule except in the extreme equatorial regions. Epithelial cell piling on the anterior capsule and epithelial growth on the posterior capsule were decreased absent. The decreased amount of epithelial cell growth in the immunotoxin-treated eyes was considered significant. No evidence of toxicity in the iris, choroid, or retina segments of the eye, was noted in any lens type.

These preliminary results, even though conducted with a small group of animals, are significant in that they suggest (1) that an immunotoxin having the capacity to bind to lens epithelial cells can prevent development of secondary cataract, and (2) it is possible to deliver immunotoxin in a polymeric carrier via an IOL.

Coating IOLs with intraocular devices comprising solutions of immunotoxin in 10% F68 provides a

46.

mechanism to deliver immunotoxin in association with the IOL. Active (as determined by its ability to kill target cells) immunotoxin is released into the IOL environment over time. All of the IOL-associated immunotoxin is released from the IOL within 24 hours.

By implanting the subject intraocular device into the anterior chamber, remnant lens epithelial cells can be prevented from proliferating, thus avoiding secondary cataracts. The use of an intraocular device either as a stand alone device or with an IOL support provides a superior means for delivery of immunotoxin by allowing for release of immunotoxin over time and protection of the immunotoxin from degradative processes in the eye. The subject methods and device provide a simple procedure for preventing secondary cataracts.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

The invention now having been fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

47.

WHAT IS CLAIMED IS:

1. An intraocular device comprising:
a biologically inert polymer and a
5 cytotoxic agent capable of binding at least
substantially specifically to epithelial cells,
wherein said cytotoxic agent is associated reversibly
with said polymer.
- 10 2. The device according to Claim 1, wherein
said cytotoxic agent is an immunotoxin.
3. The device according to Claim 2, wherein
said immunotoxin comprises an antibody at least
15 substantially specific for epithelial cells
conjugated to a toxic agent.
4. The device according to Claim 3, wherein
said antibody is a monoclonal antibody.
- 20 5. The device according to Claim 4, wherein
said toxic agent is a ricin A-chain.
6. The device according to Claim 1, wherein
25 said polymer is coated onto the surface of an
intraocular lens or an "O" ring of a form suitable
for use with an intraocular lens.
7. The device according to Claim 6, wherein
30 said "O" ring is degradable in the eye.
8. A method for preventing secondary cataracts
which form following extracapsular extraction, said
method comprising:
35 implanting, during or immediately after
extracapsular extraction, an intraocular device into
the anterior or posterior chamber of the eye, wherein

48.

said intraocular device comprises a biologically inert polymer and a cytotoxic agent capable of binding at least substantially specifically to epithelial cells, and wherein said cytotoxic agent is associated reversibly with said polymer and when released from said polymer is present in the anterior chamber for a time and in an amount sufficient to kill at least substantially all residual lens epithelial cells.

10

9. A method for preparing an intraocular device, said method comprising:

contacting a biologically inert polymer with a cytotoxic agent capable of binding at least substantially specifically to epithelial cells, so that said cytotoxic agent is associated reversibly with said polymer.

15

10. The method according to Claim 9, wherein said associated reversibly is entrapment of said cytotoxic agent within said polymer or adsorption of said cytotoxic agent to said polymer.

20

1/3




FIGURE 1

SUBSTITUTE SHEET

2/3




FIGURE 2

SUBSTITUTE SHEET

3/3




FIGURE 3
SUBSTITUTE SHEET

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/00 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 299 467 (OPHTHALMIC RESEARCH CORPORATION) 18 January 1989	1-4,8-10
Y	see page 2, line 51 - page 3, line 2 see page 3, line 21 - line 31 see page 3, line 55 - page 4, line 4 see claim 11	5
X	EP,A,0 443 809 (IOPTEx RESEARCH INC.) 28 August 1991 see page 5; example 10	1,6-10
Y	EP,A,0 267 005 (BAYLOR COLLEGE OF MEDICINE) 11 May 1988 see claims 1-10	5

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

16 February 1994

Date of mailing of the international search report

02.03.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
REMARK: Although claim 8 is directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0299467	18-01-89	US-A-	4918165	17-04-90
		AU-B-	602993	01-11-90
		AU-A-	1904388	19-01-89
		JP-A-	1100133	18-04-89
<hr/>				
EP-A-0443809	28-08-91	AU-A-	7118791	22-08-91
<hr/>				
EP-A-0267005	11-05-88	AU-B-	608257	28-03-91
		AU-A-	8066687	05-05-88
		DE-A-	3783211	04-02-93
		JP-A-	63211239	02-09-88
		US-A-	4871350	03-10-89
		US-A-	5055291	08-10-91
<hr/>				